NUCB2 and glioblastoma: Collectively, these results suggest that NUCB2 may play a critical role in establishing an immunosuppressive tumour microenvironment in GBM, potentially impairing the functionality of infiltrating immune cells or even promoting tumour‐supportive phenotypes, thereby contributing to immune evasion and aggressive clinical progression characteristic of this malignancy.